Amlan International to Showcase Natural Mineral Technology at International Production and Processing Expo (IPPE)
CHICAGO, Jan. 12, 2023 (GLOBE NEWSWIRE) -- Amlan® International, the animal health business of Oil-Dri® Corporation of America, is pleased to announce its participation in the International Production and Processing Expo (IPPE) January 24-26, 2023, in Atlanta, GA. Attendees will learn more about the latest in feed technology for animal protein producers that optimize gut health through three exciting TECHTalks, a new product showcase featuring Phylox®, and two poster presentations during the International Poultry Scientific Forum (IPSF). Amlan is also proud to be the exclusive sponsor of the IPPE Media Center. Amlan looks forward to welcoming a global audience of animal production professionals and sharing more about its range of products with attendees, media and other exhibitors at its booth, B5453.
Last year at IPPE, Amlan expanded its product portfolio with the launch of Phylox (available in select international markets). Phylox is a research-backed, natural alternative to anticoccidial drugs that supports gut health naturally thus improving productivity and, in turn, driving producers' profits. This year, Phylox will be highlighted during the expo’s new product showcase. Attendees can watch a video presentation to learn more about the company’s latest innovation.
“We look forward to speaking with producers about how Phylox, a bioactive blend of antiprotozoal phytochemicals with multiple modes of action, decreases the negative production and health effects of coccidiosis,” said Dr. Wade Robey, Vice President of Agriculture, Oil-Dri, and President, Amlan International. “Phylox is natural and can be used in “no antibiotics ever” (NAE) programs, has no withdrawal requirements, and can be fed in combination with anticoccidial vaccines preventing disease breakthrough.”
“We are excited about the success of our North American portfolio, which includes Sorbiam™ and Enterotec™. The industry reaction to these products created to optimize animal gut health has been tremendous,” according to Heath Wessels, Vice President of Sales, The Americas. “Working with our key customers, our products continue to demonstrate the efficacy of our mineral-based feed additives.”
Attendees can learn more about the latest in protein and feed technology presented during TECHTalks.
On Tuesday, January 24:
- Dr. Marc Herpfer, VP, New Technologies, Oil-Dri Corporation of America, will present “Natural Mineral Technology as an Alternative to AGPs” in B Hall, Booth B8675 at 11:00 a.m.
- Dr. Josh Payne, Dir. Technical Service, Poultry Guard, will present “Best Management Practices and Utilization of Clay-Based Litter Amendment for pH and Ammonia Control” in B Hall, Booth B3646 at 11:30 a.m.
On Wednesday, January 25:
- Mike Donohue, VP, Agri Stats, Inc. will present “The Importance of 1%, The Effect of Efficiency on Sustainability and Economic Value” in B Hall, Booth B3646 at 10:00 a.m.
“TECHTalks are an excellent way for us to provide valuable information on specific technical challenges the industry is facing,” says Dr. Aldo Rossi, Vice President, Innovation and Technical Service. “We are proud of our high-quality and efficacious mineral-based feed additives for poultry and livestock, and how they can improve the quality of animal protein. We look forward to sharing our solutions with producers.”
During the International Poultry Scientific Forum (IPSF) on January 23, Amlan experts will present two posters, selected by IPSF, detailing research designed to support optimal poultry intestinal health and bring the latest production technology to producers. The presentations will be from 4:00 p.m. to 6:00 p.m.:
- Feeding Varium® produces growth performance similar to feeding an antibiotic on-farm, by Dr. Sara (LeAnn) Johnston, Technical Service Manager, Amlan International
- A natural coccidiostat, Phylox Feed, improves performance, intestinal lesion scores, and fecal oocyst shedding of Eimeria-infected broilers, Dr. San (Chris) Ching, Senior Research Manager, Amlan International.
Amlan is continuing to proudly celebrate its 15th anniversary of providing natural mineral-based feed additives to the industry. The Amlan brand was introduced into the feed-additive market in 2007. Vertical integration allows Amlan to leverage Oil-Dri's mineral science expertise to develop novel, natural feed additives. Oil-Dri launched its first mineral-based product, an industrial floor absorbent, in 1941, and since then has mined and processed a range of unique minerals for many applications. Oil-Dri has been active in the animal health market since the 1980s, with products that assist feed flowability and pellet binding.
“As the proud exclusive sponsor of the IPPE Media Center, Amlan looks forward to building relationships with media from around the world,” says Reagan Culbertson, Vice President of Strategic Marketing, B2B. “We hope media professionals will visit the Media Center to work, network and visit with our experts about Amlan’s unique and exciting mineral technology.”
For more information on Amlan International, please visit: www.amlan.com
Company Information
Amlan is the animal health business of Oil-Dri Corporation of America, a leading global manufacturer and marketer of sorbent minerals. Oil-Dri leverages over 80 years of expertise in mineral science to selectively mine and process its unique mineral for consumer and business-to-business markets. Oil-Dri Corporation of America doing business as “Amlan International” is a publicly traded stock on the New York Stock Exchange (NYSE: ODC). Amlan International sells feed additives across the world. Product availability may vary by country, associated claims do not constitute medical claims and may differ based on government requirements.
Reagan Culbertson
Media Contact
press@amlan.com
To view this piece of content from ml.globenewswire.com, please give your consent at the top of this page.
About GlobeNewswire by notified
GlobeNewswire by notifiedGlobeNewswire by notified is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.
Subscribe to releases from GlobeNewswire by notified
Subscribe to all the latest releases from GlobeNewswire by notified by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from GlobeNewswire by notified
Borregaard ASA: EBITDA1 of NOK 442 million in the 1st quarter24.4.2024 07:00:00 CEST | Press release
Borregaard’s operating revenues reached NOK 1,975 million (NOK 1,850 million)2 in the 1st quarter of 2024. EBITDA1 increased to NOK 442 million (NOK 435 million). The result in BioSolutions increased while results in BioMaterials and Fine Chemicals were lower compared with the 1st quarter of 2023. The result in BioSolutions increased due to higher sales volume and reduced energy costs. In BioMaterials, higher sales volume was more than offset by lower sales prices and higher wood costs. Fine Chemicals had a lower result due to low bioethanol deliveries and increased costs. The net currency effects were slightly negative for the Group. Profit before tax was NOK 261 million (NOK 292 million). Earnings per share were NOK 2.01 (NOK 2.32). - We are pleased with the strong result improvement in BioSolutions and the positive sales volume development for the Group, says President and CEO Per A. Sørlie. Contacts: Director Investor Relations, Knut-Harald Bakke, +47 905 79 164 Director Communicat
[Ad hoc announcement pursuant to Art. 53 LR] Roche sales increase by 2% (CER) in first quarter with both divisions growing in high single digit ex COVID-1924.4.2024 07:00:00 CEST | Press release
Group sales grew by 2%1 at constant exchange rates (CER) (-6% in CHF), driven by the strong growth of newer medicines and diagnostics. Excluding COVID-19-related products, sales increased by 7%. Going forward, there will be no further material impact of COVID-19 sales declineDue to the appratioss fn of the Swiranc against most currencies, sales were 6% lower when reported in CHFPharmaceuticals Divisionbase business2 grew by 7%, driven by strong sales of medicines to treat severe diseases, such as Vabysmo (eye diseases), Phesgo (breast cancer), Ocrevus (multiple sclerosis), Polivy (blood cancer) and Hemlibra (haemophilia A). Divisional sales growth was 2%, reflecting the impact of the expected decline in sales of the COVID-19 medicine Ronapreve Diagnostics Division base business2 grew by 8%, supported by growth across all regions because of demand for immunodiagnostic products, clinical chemistry tests and advanced staining solutions. As this growth was partially offset by the lower dem
Vivoryon Therapeutics N.V. Reports Full Year 2023 Financial Results and Provides Varoglutamstat and Strategic Updates24.4.2024 07:00:00 CEST | Press release
Vivoryon Therapeutics N.V. Reports Full Year 2023 Financial Results and Provides Varoglutamstat and Strategic Updates In-depth analysis of VIVIAD Phase 2b results is ongoing, including pre-specified and exploratory endpoints; findings to date are consistent with previously announced topline data observing no statistically significant or clinically meaningful effect of varoglutamstat on cognition and function in early AD up to 600mg twice a day (BID) doseStatistically significant improvement in kidney function observed with varoglutamstat 600mg BID in VIVIAD over two years based on pre-specified analysis of the estimated glomerular filtration rateCompany plans to explore potential of varoglutamstat in kidney disease in a shift of strategic focus towards inflammatory and fibrotic disorders VIVA-MIND Phase 2 study to be discontinued early, in H2 2024, which will enable accelerated data analysis and inform varoglutamstat development strategyCompany is taking steps to reduce cash utilizatio
Wereldhave Trading update Q1 202424.4.2024 07:00:00 CEST | Press release
Full Service Center footfall continues to power ahead: 10% above Q1 2023Retail sales +5%, well above inflationPolarizing leasing market in the Benelux with several expanding formulas but also some bankruptciesLeasing spreads in the Netherlands moving into positive territoryRent collection >97% underpinning tenant qualityLTV improved to 41.5% due to positive Belgian revaluations (ERV driven) and targeted CAPEXUpdate on short-term strategic focus: rotating capital out of the Netherlands to further reduce LTVFull Service Center Sterrenburg awarded with the 2024 Kern annual development awardForecast FY 2024 DRPS € 1.75 reiterated Attachment Trading update Q1 2024 Wereldhave N.V.
IMCD Spain expands its Pharmaceuticals presence with the acquisition of Cobapharma24.4.2024 07:00:00 CEST | Press release
ROTTERDAM, The Netherlands 24 April 2024 – IMCD N.V. (“IMCD” or “Company”), a leading distributor of speciality chemicals and ingredients, today announces that IMCD Spain has signed an agreement to acquire 100% of the shares in Cobapharma, S.L.U, a European distributor in the pharmaceutical and nutraceutical industry. Established in 2011 and headquartered in Barcelona, Spain, Cobapharma provides an extensive portfolio of Active Pharmaceutical Ingredients (APIs) as well as nutraceutical ingredients. With 20 employees, Cobapharma represents leading suppliers and generated a revenue of approximately EUR 19 million in the financial year that ended December 31, 2023. ‘Cobapharma is a rapidly growing distributor in the pharmaceutical and nutraceutical industry. Their esteemed reputation for providing high-quality APIs and nutraceutical ingredients perfectly complements our existing portfolio. The alignment of our business models will enhance our ability to serve our customers and partners’ c